BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Dayvigo (Lemborexant) readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Dayvigo (Lemborexant)\, from ClinicalTria
 ls.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07384429-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20261201
DTEND;VALUE=DATE:20261202
SUMMARY:Dayvigo (Lemborexant): Phase 4 readout est. (NCT07384429)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 4.\nStudy: Effects of Lemborexant
  on Motor-sleep Comorbidity in Parkinson's Disease\nEstimated primary comp
 letion: 1 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lemborexant#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07384429
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06779149-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Dayvigo (Lemborexant): Phase na readout est. (NCT06779149)
DESCRIPTION:Dayvigo (Lemborexant)\, phase na.\nStudy: Efficacy of CBT-I and
  Lemborexant Medication for Different Subtypes of Chronic Insomnia\nEstima
 ted primary completion: February 2027. This is a ClinicalTrials.gov estima
 te\, not a confirmed readout date\, and it can move.\nDrug page: https://a
 ssetmemo.bio/drug/lemborexant#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06779149
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06648681-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270430
DTEND;VALUE=DATE:20270501
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT06648681)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2.\nStudy: Lemborexant to Prevent
  Post-operative Delirium in Cardiac Surgery Patients\nEstimated primary co
 mpletion: 30 April 2027. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/lemborexant#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT06648681
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06928766-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270501
DTEND;VALUE=DATE:20270502
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT06928766)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2.\nStudy: Effects of Eszopiclone
  and Lemborexant in People With OSA With a Low Arousal Threshold Who Have 
 Difficulty Sleeping\nEstimated primary completion: 1 May 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/lemborexant#upcoming-events\nReg
 istry record: https://clinicaltrials.gov/study/NCT06928766
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06874855-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dayvigo (Lemborexant): Phase 4 readout est. (NCT06874855)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 4.\nStudy: Lemborexant in Delayed
  Sleep Phase Syndrome\nEstimated primary completion: 31 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lemborexant#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT06874855
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05463861-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Dayvigo (Lemborexant): Phase 4 readout est. (NCT05463861)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 4.\nStudy: Lemborexant in Delayed
  Sleep Phase Syndrome\nEstimated primary completion: 31 May 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/lemborexant#upcoming-events\n
 Registry record: https://clinicaltrials.gov/study/NCT05463861
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07918300-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20270630
DTEND;VALUE=DATE:20270701
SUMMARY:Dayvigo (Lemborexant): Phase 4 readout est. (NCT07918300)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 4.\nStudy: Lemborexant on Periope
 rative Sleep Quality in Patients Undergoing Breast Cancer Surgery\nEstimat
 ed primary completion: 30 June 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/lemborexant#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07918300
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06823752-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT06823752)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2.\nStudy: A Dual Orexin Receptor
  Antagonist to Reduce Biomarkers of Neurodegeneration in Adults With Insom
 nia.\nEstimated primary completion: December 2027. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/lemborexant#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT06823752
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07811401-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT07811401)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2.\nStudy: Lemborexant on Periope
 rative Sleep Quality in Patients Undergoing Thoracoscopic Surgery\nEstimat
 ed primary completion: 31 December 2027. This is a ClinicalTrials.gov esti
 mate\, not a confirmed readout date\, and it can move.\nDrug page: https:/
 /assetmemo.bio/drug/lemborexant#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07811401
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903038-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT07903038)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2.\nStudy: Lemborexant on Periope
 rative Sleep Quality in Patients With Parkinson's Disease Undergoing Deep 
 Brain Stimulation\nEstimated primary completion: 31 December 2027. This is
  a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can
  move.\nDrug page: https://assetmemo.bio/drug/lemborexant#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07903038
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07903051-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT07903051)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2.\nStudy: Lemborexant on Periope
 rative Sleep Quality in Patients With Brain Tumor Undergoing Surgery\nEsti
 mated primary completion: 31 December 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/lemborexant#upcoming-events\nRegistry record: https
 ://clinicaltrials.gov/study/NCT07903051
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07407400-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Dayvigo (Lemborexant): Phase 4 readout est. (NCT07407400)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 4.\nStudy: Lemborexant for Sleep 
 and Delirium Prevention in Elderly ICU Patients\nEstimated primary complet
 ion: 31 December 2027. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/lemborexant#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT07407400
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07683442-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:Dayvigo (Lemborexant): Phase 1/2 readout est. (NCT07683442)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 1/2.\nStudy: The Optimal One-Mont
 h Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patient
 s With Low Arousal Threshold\nEstimated primary completion: 30 June 2028. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/lemborexant#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07683442
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07802990-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Dayvigo (Lemborexant): Phase 1/2 readout est. (NCT07802990)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 1/2.\nStudy: Lemborexant for Cann
 abis Use Disorder\nEstimated primary completion: November 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/lemborexant#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07802990
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06093126-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20281211
DTEND;VALUE=DATE:20281212
SUMMARY:Dayvigo (Lemborexant): Phase 4 readout est. (NCT06093126)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 4.\nStudy: Lemborexant for Insomn
 ia in a Patient With Dementia: An N-of-1 Trial\nEstimated primary completi
 on: 11 December 2028. This is a ClinicalTrials.gov estimate\, not a confir
 med readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug
 /lemborexant#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT06093126
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06981195-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20290730
DTEND;VALUE=DATE:20290731
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT06981195)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2.\nStudy: Effects of Lemborexant
  on Insomnia and Its Relationship to Mood and Behavior on Opioid Use Disor
 der Subjects\nEstimated primary completion: 30 July 2029. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/lemborexant#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06981195
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07695285-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20290901
DTEND;VALUE=DATE:20290902
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT07695285)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2.\nStudy: Lemborexant Use for Co
 gnition Improvement in Postoperative Delirium in Elderly Patients: A Rando
 mized Controlled Trial\nEstimated primary completion: 1 September 2029. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/lemborexant#upcoming-ev
 ents\nRegistry record: https://clinicaltrials.gov/study/NCT07695285
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07840638-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20291130
DTEND;VALUE=DATE:20291201
SUMMARY:Dayvigo (Lemborexant): Phase 4 readout est. (NCT07840638)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 4.\nStudy: How Well and Safely Do
 es Lemborexant Work for People Who Wake up at Night to Urinate (LENS)\nEst
 imated primary completion: 30 November 2029. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/lemborexant#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT07840638
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06274528-735@assetmemo.bio
DTSTAMP:20261121T005853Z
DTSTART;VALUE=DATE:20300331
DTEND;VALUE=DATE:20300401
SUMMARY:Dayvigo (Lemborexant): Phase 2 readout est. (NCT06274528)
DESCRIPTION:Dayvigo (Lemborexant)\, phase 2\, Alzheimer's Disease.\nStudy: 
 DORA and LP in Alzheimer's Disease Biomarkers\nEstimated primary completio
 n: 31 March 2030. This is a ClinicalTrials.gov estimate\, not a confirmed 
 readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/lem
 borexant#upcoming-events\nRegistry record: https://clinicaltrials.gov/stud
 y/NCT06274528
URL:https://assetmemo.bio/drug/lemborexant#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
